Nomifensine

CAT: 0804-HY-B1110-01Size: 50 mgDry Ice: NoHazardous: No
CAT#:0804-HY-B1110-01Size:50 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Nomifensine ((±) -Nomifensine) is a potent norepinephrine (NE) and dopamine (DA) reuptake inhibitor. Nomifensine inhibits uptake of NE, DA and 5-HT in rat brain synaptosomes, with IC50 values of 6.6 nM, 48 nM and 830 nM, and Ki values of 4.7 nM, 26 nM and 4000 nM, respectively. Nomifensine has antidepressant and analgesic effects. Nomifensine is used in neurodegenerative diseases, compound addiction, and pain research[1][2][3][4][5][6][7].
CAS Number
[24526-64-5]
Product Name Alternative
(±) -Nomifensine; Nomifensin
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Adrenergic Receptor; Dopamine Receptor
Type
Reference compound
Related Pathways
GPCR/G Protein; Neuronal Signaling
Applications
Neuroscience-Neuromodulation
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/Nomifensine.html
Concentration
10mM
Purity
98.93
Solubility
DMSO : ≥ 100 mg/mL
Smiles
NC1=CC=CC2=C1CN(C)CC2C3=CC=CC=C3
Molecular Formula
C16H18N2
Molecular Weight
238.33
Precautions
H302, H315, H319, H335
References & Citations
[1]Hyttel J, et al. Neurochemical profile of Lu 19-005, a potent inhibitor of uptake of dopamine, noradrenaline, and serotonin. J Neurochem. 1985 May;44 (5) :1615-22.|[2]Tuomisto J. Nomifensine and its derivatives as possible tools for studying amine uptake. Eur J Pharmacol. 1977 Mar 21;42 (2) :101-6. |[3]Tejani-Butt S, et al. Strain-dependent modification of behavior following antidepressant treatment. Prog Neuropsychopharmacol Biol Psychiatry. 2003 Feb;27 (1) :7-14. |[4]Katz NS, et al. Effects of acute and sustained administration of the catecholamine reuptake inhibitor nomifensine on the firing activity of monoaminergic neurons. J Psychopharmacol. 2010 Aug;24 (8) :1223-35.|[5]Kang SH, et al. Transformation of nomifensine using ionizing radiation and exploration of its anticancer effects in MCF-7 cells. Exp Ther Med. 2022 Apr;23 (4) :306.|[6]Gilbert AK, et al. Characterization of the analgesic properties of nomifensine in rats. Pharmacol Biochem Behav. 2001 Apr;68 (4) :783-7.|[7]Melamed E, et al. Suppression of MPTP-induced dopaminergic neurotoxicity in mice by nomifensine and L-DOPA. Brain Res. 1985 Sep 9;342 (2) :401-4.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Citation 01
BioRxiv. 2024 June 12.|Biotechnol Bioeng. 2021 Dec;118 (12) :4687-4698.|Glia. 2017 Aug;65 (8) :1251-1263.|Neurosci Lett. 2025 Sep 3:866:138373.|bioRxiv. 2023 Aug 3.|Commun Biol. 2021 Sep 13;4 (1) :1065.

Related Products

CatalogName

Alternative Products

CatalogName
MBS3610716-01Nomifensine
M22410-01Nomifensine (maleate)
T7070-01Nomifensine maleate
sc-253197ANomifensine maleate salt
TRC-N635950-50MGNomifensine Maleic Acid Salt
TRC-N635952-50MGNomifensine-d3 Maleic Acid Salt

Popular Products